Clobetasone butyrate
Brand names: Eumovate
Clobetasone butyrate is a moderately potent topical corticosteroid used for inflammatory skin conditions such as eczema and dermatitis where a mild steroid is insufficient.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It activates glucocorticoid receptors in skin cells to reduce inflammation, suppress local immune activity and cause vasoconstriction.
Prescribing in practice
- Although less potent than the strongest steroids, prolonged or extensive use can still cause skin atrophy and, rarely, systemic absorption, so apply sparingly for the shortest effective period.
- Use cautiously on the face and in flexures, and avoid applying to infected skin without appropriate antimicrobial cover.
- Step down to an emollient-led regimen as the flare settles and review if the condition fails to improve.
Monitoring
Monitor the treated skin clinically for response and for local corticosteroid side-effects, particularly with longer courses.
Counselling the patient
- Apply thinly to the affected area and continue regular emollients between flares.
- Use only for the duration advised and avoid spreading onto unaffected skin.
- Seek advice if the rash worsens or shows signs of infection.
Evidence & guidelines
Use reflects standard topical corticosteroid potency selection in line with NICE eczema and dermatitis guidance.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD